Canadian company PKA SoftTouch revolutionized syringes with the first painless microneedle in 170 years. Canadian Business Journal

SELWYN, ON, Oct. 26, 2022 (GLOBE NEWSWIRE) — Canadian MedTech company PKA SoftTouch’s patented microneedle has completed veterinary clinical trials at the University of Guelph, Ontario. The results demonstrate that the device significantly outperforms conventional syringe injection by enhancing drug delivery by shortening the time to peak action.

Syringe technology hasn’t evolved in over 170 years. PKA SoftTouch has completely reimagined the concept of injection and is painless, easy to use and requires no sharps disposal. The innovative PKA SoftTouch Micro-Needle has shown that a shallow delivery process enhances drug uptake, bioavailability and efficacy compared to the traditional deep muscle method of injection with a syringe.

The global injectable drug market is vast, with approximately 16 billion syringe injections performed each year. According to the World Health Organization (WHO), he is expected to have 2 billion cases of needle deficiency this year. PKA SoftTouch is positioned as a superior vaccine delivery device due to its low manufacturing cost and unprecedented rapid, safe and painless injectable drug delivery.

The device hides a small needle that goes 1.5 mm (about 0.06 inch) below the skin surface, avoiding all nerves and is invisible to the user. PKA’s microneedles were designed to help approximately 27% of the population who experience “trypanophobia” (needle phobia) and, as a result, avoid treatment.

The study concluded that the animals responded wonderfully to microneedle injections and did not express any discomfort. The easy-to-use design made all technicians familiar with using the device in no time. Dr. Pankaj Modi, CEO of PKA SoftTouch and inventor of the Micro-Needle, said: As the global pandemic expands medical capacity around the world and more patients require injections for a variety of health reasons, these trials will help develop technologies that provide better and more efficient treatments. showing what we have. “

Funding of $1,150,000 to complete the exam was raised from the company’s successful equity crowdfunding campaign hosted by FrontFundr, Canada’s leading online private market investment platform. “Going forward, our focus will be on commercializing the device for the animal market and conducting human trials,” he said.

Modi said their device is a platform technology with high-value applications in multiple medical fields. Microneedles respond to the growing global need to administer life-saving drugs to people and animals suffering from chronic diseases such as diabetes.

Our revenue model is license-based and we receive royalties through licensing agreements with pharmaceutical companies that license, manufacture, prefill and sell our technology.

“Pharmaceutical companies want proof that the device works,” Modi says. We are executing our go-to-market strategy and are in discussions with companies expected to adopt this innovative technology. ”

About PKA Soft Touch

PKA SoftTouch Corp. is a cutting-edge R&D company that has created unique, innovative and proprietary devices. PKA SoftTouch microneedles. The PKA SoftTouch Micro-Needle meets the need for humans and animals to receive life-saving medication in a painless, safe, inexpensive and simple way. The world’s patented pre-filled microneedle technology is the only effective device that injects drugs into the nerveless and painless skin layers. It is positioned to replace traditional syringe-based drug delivery and aims to improve the quality of life for millions of users worldwide.

Connect with PKA SoftTouch: Website | Facebook | LinkedIn | Instagram | Twitter

This communication is for informational purposes only.

CBJ Newsmaker